MONOCLONAL-ANTIBODY THERAPY WITH CICLOSPORIN AND STEROIDS IN NONMATCHED CADAVERIC RENAL-TRANSPLANTS NEPHRON Gordon, R. D., Starzl, T. E., Fung, J. J., Iwatsuki, S., Esquivel, C. O., Tzakis, A., Todo, S. 1987; 46: 56-59

Abstract

Thirty-six ciclosporin-prednisone-treated recipients of nonmatched cadaver renal allografts were given a course of Orthoclone OKT3 monoclonal antibody for steroid-resistant cell-mediated rejection. Although side effects were common, only 2 patients had to be withdrawn from therapy and there were no deaths related to therapy. Twenty-three (63.9%) allografts were rescued with OKT3 therapy and 21 (58.3%) of the grafts have continued to function well. We conclude that OKT3 is an effective agent for the treatment of steroid-resistant cell-mediated rejection and that rebound rejection can be prevented in most patients if adequate therapy with ciclosporin-prednisone is maintained.

View details for Web of Science ID A1987J437000009

View details for PubMedID 3306426